Loading quotes...

Forecast

The analysts' average price target is €47.78 (-24.61%). The median is €46.88 (-26.03%).

Buy	15
Hold	18
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Exelixis prepares zanzalintinib launch while CABOMETYX growth in NET lags

Exelixis is gearing for a potential late-2026 launch of zanzalintinib (zanza) in third-line colorectal cancer and has budgeted launch expenses into guidance. The company aims to expand CABOMETYX to a roughly $3 billion franchise via deeper penetration in renal cell carcinoma and neuroendocrine tumors, but NET uptake has ramped slower than expected due to the disease’s indolent treatment dynamics. Exelixis assumes CABOMETYX generics may enter in 2031, is advancing zanza combinations in RCC and NET, and is prioritizing R&D, business development and share repurchases with about $600 million remaining in buyback authority. » More on finance.yahoo.com
FDA delays approval decision on Zanzalintinib — Exelixis shares fall

The US FDA has classified updated safety and efficacy data as a substantial amendment and postponed the review of the approval application for Zanzalintinib plus atezolizumab by three months; the target action date shifts from December 3, 2026 to March 3, 2027. Exelixis reported the development in a Form 8-K with the SEC, and the stock fell about 3.5% in premarket trading. Analysts and investors had priced in a December approval, so the delay means increased short-term risk and valuation pressure on the shares. » More on de.investing.com
Exelixis reaches new all-time high at $57.68

The stock of Exelixis marked a new all-time high at $57.68. In the second quarter of 2026 the company beat the adjusted EPS expectation with $0.91, but slightly missed revenue expectations and therefore cut its revenue guidance for 2026. The CABOMETYX franchise continued to contribute to growth; the global cabozantinib franchise rose 13% to $806 million. Six analysts recently raised earnings estimates, while BMO Capital Exelixis with » More on de.investing.com
Exelixis: zanzalintinib ahead of FDA approval after strong phase-3 data

Zanzalintinib is seen as a central hope for Exelixis and is close to possible FDA approval after phase-3 (CABINET) data that showed up to a 74% reduction in risk of progression in neuroendocrine tumors. The company also reported strong quarterly results with revenue of USD 610.8 million in Q1 2026 and earnings per share above expectations. Exelixis therefore remains well positioned both clinically and commercially. » More on finanzen.net
Exelixis reports strong Q1 2026 results; Renaissance Technologies maintains large stake

Exelixis posted Q1 2026 revenue of $610.8 million, up 10% year‑over‑year, and non‑GAAP diluted EPS of $0.87, beating estimates. Q1 non‑GAAP net income rose 30% to $232.8 million and trailing 12‑month net profit margin expanded to 35.1%. Renaissance Technologies held 13.7 million Exelixis shares in its Q1 2026 filings, down about 1% from the prior quarter and a long‑standing position in the fund's portfolio. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Exelixis has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Exelixis had revenue of €585.02M and net profit of €193.7M

(EUR)	October 2026	YoY
Revenue	585.02M	14.91%
Gross profit	561.72M	13.87%
Net profit	193.7M	17.49%
EBITDA	257.32M	16.27%

Fundamentals

Metric	Value
Market capitalization	€15.76B
Number of shares	251.36M
52-week high/low	€66.43 - €35.80
Dividends	No
Beta	0.42
P/E ratio	20.17
PEG ratio	0.49
P/B ratio	9.36
P/S ratio	7.00

Company profile

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.